PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCLPeter Dreger, Mehdi Hamadani, Anna Sureda et al.|Blood Advances|2019Cited by 115
Post-transplant cyclophosphamide versus anti-thymocyte globulin for graft-versus-host disease prevention in haploidentical transplantation for adult acute lymphoblastic leukemiaArnon Nagler, Mohamad Mohty, Depei Wu et al.|Haematologica|2020Cited by 56
<scp>CD34</scp>+ cell dose effects on clinical outcomes after T‐cell replete haploidentical allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia using peripheral blood stem cells. A study from the acute leukemia working Party of the European Society for blood and marrow transplantation (<scp>EBMT</scp>)Enrico Maffini, Mohamad Mohty, Myriam Labopin et al.|American Journal of Hematology|2020Cited by 39
Haploidentical Versus Matched Unrelated Donor Transplants Using Post-Transplantation Cyclophosphamide for LymphomasAlberto Mussetti, Anna Sureda, Abraham S. Kanate et al.|Transplantation and Cellular Therapy|2022Cited by 22
Impact of CD34+ Cell Dose on Clinical Outcomes after Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from Haploidentical Donors in AML Patients. a Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)Enrico Maffini, Mohamad Mohty, Myriam Labopin et al.|Transplantation and Cellular Therapy|2020Cited by 0